Synaptic vesicle protein 2A: Basic facts and role in synaptic function

European Journal of Neuroscience

Volumn 38, Issue 11, 2013, Pages 3529-3539

  Mendoza Torreblanca, Julieta Griselda ^a   Vanoye Carlo, América ^a   Phillips Farfán, Bryan Víctor ^a   Carmona Aparicio, Liliana ^a   Gómez Lira, Gisela ^b  

^a INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Epilepsy; Neurotransmitter; Neurotransmitter release; Synapse; Synaptic proteins

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; CALCIUM ION; ETIRACETAM; GLUTAMIC ACID; MEMBRANE PROTEIN; MICRORNA; MICRORNA 485; NEUROTRANSMITTER; PROTEOGLYCAN; SYNAPTIC VESICLE PROTEIN 2A; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ACTION POTENTIAL; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTICONVULSANT THERAPY; BINDING SITE; BRAIN; BRAIN CORTEX; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG PROTEIN BINDING; ELECTROPHYSIOLOGY; EPILEPSY; EPILEPTIC STATE; EXOCYTOSIS; GABAERGIC TRANSMISSION; GEL; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; GENETICS; GLYCOSYLATION; HIPPOCAMPAL CA1 REGION; HUMAN; NERVE ENDING; NERVE EXCITABILITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SEIZURE; SV2A GENE; SYNAPSE VESICLE; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE;

EPILEPSY; NEUROTRANSMITTER; NEUROTRANSMITTER RELEASE; SYNAPSE; SYNAPTIC PROTEINS;

ANIMALS; EPILEPSY; HUMANS; MEMBRANE GLYCOPROTEINS; NERVE TISSUE PROTEINS; SYNAPSES; SYNAPTIC TRANSMISSION; SYNAPTIC VESICLES;

EID: 84897085781     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12360     Document Type: Review

References (81)

1. Bajjalieh, S.M., Peterson, K., Shinghal, R. & Scheller, R.H. (1992) SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science, 257, 1271-1273.
2. Bajjalieh, S.M., Peterson, K., Linial, M. & Scheller, R.H. (1993) Brain contains two forms of synaptic vesicle protein 2. Proc. Natl. Acad. Sci. USA, 90, 2150-2154.
3. Bajjalieh, S.M., Frantz, G.D., Weimann, J.M., McConnell, S.K. & Scheller, R.H. (1994) Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J. Neurosci., 14, 5223-5235.
4. Bindra, P.S., Knowles, R. & Buckley, K.M. (1993) Conservation of the amino acid sequence of SV2, a transmembrane transporter in synaptic vesicles and endocrine cells. Gene, 137, 299-302.
5. Bostick, D.L. & Berkowitz, M.L. (2004) Exterior site occupancy infers chloride-induced proton gating in a prokaryotic homolog of the ClC chloride channel. Biophys. J., 87, 1686-1696.
6. Bragina, L., Fattorini, G., Giovedi, S., Melone, M., Bosco, F., Benfenati, F. & Conti, F. (2011) Analysis of synaptotagmin, SV2, and Rab3 expression in cortical glutamatergic and GABAergic axon terminals. Front. Cell Neurosci., 5, 32.
7. Brunger, A.T. (2005) Structure and function of SNARE and SNARE-interacting proteins. Q. Rev. Biophys., 38, 1-47.
8. Buckley, K. & Kelly, R.B. (1985) Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J. Cell Biol., 100, 1284-1294.
9. Budzinski, K.L., Allen, R.W., Fujimoto, B.S., Kensel-Hammes, P., Belnap, D.M., Bajjalieh, S.M. & Chiu, D.T. (2009) Large structural change in isolated synaptic vesicles upon loading with neurotransmitter. Biophys. J., 97, 2577-2584.
10. Carreno, M. (2007) Levetiracetam. Drugs Today (Barc.), 43, 769-794.
11. 2+-induced exocytosis. J. Neurosci., 29, 883-897.
12. Cohen, D. & Segal, M. (2011) Network bursts in hippocampal microcultures are terminated by exhaustion of vesicle pools. J. Neurophysiol., 106, 2314-2321.
13. Crowder, K.M., Gunther, J.M., Jones, T.A., Hale, B.D., Zhang, H.Z., Peterson, M.R., Scheller, R.H., Chavkin, C. & Bajjalieh, S.M. (1999) Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc. Natl. Acad. Sci. USA, 96, 15268-15273.
14. Custer, K.L., Austin, N.S., Sullivan, J.M. & Bajjalieh, S.M. (2006) Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J. Neurosci., 26, 1303-1313.
15. Dibbens, L.M., Hodgson, B.L., Helbig, K.L., Oliver, K.L., Mulley, J.C., Berkovic, S.F. & Scheffer, I.E. (2012) Rare protein sequence variation in SV2A gene does not affect response to levetiracetam. Epilepsy Res., 101, 277-279.
16. Dong, M., Yeh, F., Tepp, W.H., Dean, C., Johnson, E.A., Janz, R. & Chapman, E.R. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science, 312, 592-596.
17. Dong, M., Liu, H., Tepp, W.H., Johnson, E.A., Janz, R. & Chapman, E.R. (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell, 19, 5226-5237.
18. Douaud, M., Feve, K., Pituello, F., Gourichon, D., Boitard, S., Leguern, E., Coquerelle, G., Vieaud, A., Batini, C., Naquet, R., Vignal, A., Tixier-Boichard, M. & Pitel, F. (2011) Epilepsy caused by an abnormal alternative splicing with dosage effect of the SV2A gene in a chicken model. PLoS ONE, 6, e26932.
19. Ellis, R.J. (2001) Macromolecular crowding: obvious but underappreciated. Trends Biochem. Sci., 26, 597-604.
20. Feany, M.B., Lee, S., Edwards, R.H. & Buckley, K.M. (1992) The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell, 70, 861-867.
21. Feng, G., Xiao, F., Lu, Y., Huang, Z., Yuan, J., Xiao, Z., Xi, Z. & Wang, X. (2009) Down-regulation of synaptic vesicle protein 2A in the anterior temporal neocortex of patients with intractable epilepsy. J. Mol. Neurosci., 39, 354-359.
22. GeneCards (2013) Available http://www.genecards.org.
23. Gillard, M., Chatelain, P. & Fuks, B. (2006) Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur. J. Pharmacol., 536, 102-108.
24. Gingrich, J.A., Andersen, P.H., Tiberi, M., el Mestikawy, S., Jorgensen, P.N., Fremeau, R.T. Jr. & Caron, M.G. (1992) Identification, characterization, and molecular cloning of a novel transporter-like protein localized to the central nervous system. FEBS Lett., 312, 115-122.
25. Goraya, J.S., Khurana, D.S., Valencia, I., Melvin, J.J., Cruz, M., Legido, A. & Kothare, S.V. (2008) Intravenous levetiracetam in children with epilepsy. Pediatr. Neurol., 38, 177-180.
26. Gronborg, M., Pavlos, N.J., Brunk, I., Chua, J.J., Münster-Wandowski, A., Riedel, D., Ahnert-Hilger, G., Urlaub, H. & Jahn, R. (2010) Quantitative comparison of glutamatergic and GABAergic synaptic vesicles unveils selectivity for few proteins including MAL2, a novel synaptic vesicle protein. J. Neurosci., 60, 2-12.
27. de Groot, M., Toering, S.T., Boer, K., Spliet, W.G., Heimans, J.J., Aronica, E. & Reijneveld, J.C. (2010) Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex. Neuro-Oncology, 12, 265-273.
28. de Groot, M., Aronica, E., Heimans, J.J. & Reijneveld, J.C. (2011) Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. Neurology, 77, 532-539.
29. Hanaya, R., Hosoyama, H., Sugata, S., Tokudome, M., Hirano, H., Tokimura, H., Kurisu, K., Serikawa, T., Sasa, M. & Arita, K. (2012) Low distribution of synaptic vesicle protein 2A and synaptotagimin-1 in the cerebral cortex and hippocampus of spontaneously epileptic rats exhibiting both tonic convulsion and absence seizure. Neuroscience, 221, 12-20.
30. Holyoake, J. & Sansom, M.S. (2007) Conformational change in an MFS protein: MD simulations of LacY. Structure, 15, 873-884.
31. 2+ transporters but control glucose-evoked granule recruitment. J. Cell Sci., 118, 5647-5660.
32. Janz, R. & Sudhof, T.C. (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience, 94, 1279-1290.
33. 2+ regulators in neurotransmitter release. Neuron, 24, 1003-1016.
34. Kaminski, R.M., Gillard, M., Leclercq, K., Hanon, E., Lorent, G., Dassesse, D., Matagne, A. & Klitgaard, H. (2009) Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia, 50, 1729-1740.
35. Kaminski, R.M., Gillard, M. & Klitgaard, H. (2012) Targeting SV2A for discovery of antiepileptic drugs. In Noebels, J.L., Avoli, M., Rogawski, M.A., Olsen, R.W. & Delgado-Escueta, A.V. (Eds), Jasper's Basic Mechanisms of the Epilepsies [Internet], 4th edition. Bethesda (MD), National Center for Biotechnology Information (US). Available http://www.ncbi.nlm.nih.gov/books/NBK98183/.
36. Kasahara, T. & Kasahara, M. (1998) Tryptophan 388 in putative transmembrane segment 10 of the rat glucose transporter Glut1 is essential for glucose transport. J. Biol. Chem., 273, 29113-29117.
37. Knake, S., Gruener, J., Hattemer, K., Klein, K.M., Bauer, S., Oertel, W.H., Hamer, H.M. & Rosenow, F. (2008) Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J. Neurol. Neurosur. Ps., 79, 588-589.
38. Kwon, S.E. & Chapman, E.R. (2012) Glycosylation is dispensable for sorting of synaptotagmin 1 but is critical for targeting of SV2 and synaptophysin to recycling synaptic vesicles. J. Biol. Chem., 287, 35658-35668.
39. Lazzell, D.R., Belizaire, R., Thakur, P., Sherry, D.M. & Janz, R. (2004) SV2B regulates synaptotagmin 1 by direct interaction. J. Biol. Chem., 279, 52124-52131.
40. Leberer, E., Charuk, J.H., Green, N.M. & MacLennan, D.H. (1989) Molecular cloning and expression of cDNA encoding a lumenal calcium binding glycoprotein from sarcoplasmic reticulum. Proc. Natl. Acad. Sci. USA, 86, 6047-6051.
41. Lowe, A.W., Madeddu, L. & Kelly, R.B. (1988) Endocrine secretory granules and neuronal synaptic vesicles have three integral membrane proteins in common. J. Cell Biol., 106, 51-59.
42. Lynch, B.A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S.M., Matagne, A. & Fuks, B. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. USA, 101, 9861-9866.
43. Lynch, B.A., Matagne, A., Brannstrom, A., von Euler, A., Jansson, M., Hauzenberger, E. & Soderhall, J.A. (2008) Visualization of SV2A conformations in situ by the use of protein tomography. Biochem. Bioph. Res. Co., 375, 491-495.
44. Lynch, J.M., Tate, S.K., Kinirons, P., Weale, M.E., Cavalleri, G.L., Depondt, C., Murphy, K., O'Rourke, D., Doherty, C.P., Shianna, K.V., Wood, N.W., Sander, J.W., Delanty, N., Goldstein, D.B. & Sisodiya, S.M. (2009) No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Epilepsy Res., 83, 44-51.
45. Lyseng-Williamson, K.A. (2011) Levetiracetam: a review of its use in epilepsy. Drugs, 71, 489-514.
46. Margineanu, D.G. & Wulfert, E. (1995) ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo. Eur. J. Pharmacol., 286, 321-325.
47. Maritzen, T., Keating, D.J., Neagoe, I., Zdebik, A.A. & Jentsch, T.J. (2008) Role of the vesicular chloride transporter ClC-3 in neuroendocrine tissue. J. Neurosci., 28, 10587-10598.
48. Mattheisen, M., Muhleisen, T.W., Strohmaier, J., Treutlein, J., Nenadic, I., Alblas, M., Meier, S., Degenhardt, F., Herms, S., Hoffmann, P., Witt, S.H., Giegling, I., Sauer, H., Schulze, T.G., Rujescu, D., Nothen, M.M., Rietschel, M. & Cichon, S. (2012) Genetic variation at the synaptic vesicle gene SV2A is associated with schizophrenia. Schizophr. Res., 141, 262-265.
49. Matveeva, E.A., Vanaman, T.C., Whiteheart, S.W. & Slevin, J.T. (2007) Asymmetric accumulation of hippocampal 7S SNARE complexes occurs regardless of kindling paradigm. Epilepsy Res., 73, 266-274.
50. Meehan, A.L., Yang, X., McAdams, B.D., Yuan, L. & Rothman, S.M. (2011) A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. J. Neurophysiol., 106, 1227-1239.
51. Meehan, A.L., Yang, X., Yuan, L.L. & Rothman, S.M. (2012) Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia, 53, 469-476.
52. Neher, E. & Marty, A. (1982) Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells. Proc. Natl. Acad. Sci. USA, 79, 6712-6716.
53. Nowack, A., Yao, J., Custer, K.L. & Bajjalieh, S.M. (2010) SV2 regulates neurotransmitter release via multiple mechanisms. Am. J. Physiol.-Cell Ph., 299, C960-C967.
54. Nowack, A., Malarkey, E.B., Yao, J., Bleckert, A., Hill, J. & Bajjalieh, S.M. (2011) Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. PLoS ONE, 6, e29560.
55. Ohno, Y., Ishihara, S., Terada, R., Kikuta, M., Sofue, N., Kawai, Y., Serikawa, T. & Sasa, M. (2009) Preferential increase in the hippocampal synaptic vesicle protein 2A (SV2A) by pentylenetetrazole kindling. Biochem. Bioph. Res. Co., 390, 415-420.
56. Ohno, Y., Okumura, T., Terada, R., Ishihara, S., Serikawa, T. & Sasa, M. (2012) Kindling-associated SV2A expression in hilar GABAergic interneurons of the mouse dentate gyrus. Neurosci. Lett., 510, 93-98.
57. Perry, J.L., Dembla-Rajpal, N., Hall, L.A. & Pritchard, J.B. (2006) A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport. J. Biol. Chem., 281, 38071-38079.
58. PhosphoSite (2013) Available http://www.phosphosite.org.
59. Pyle, R.A., Schivell, A.E., Hidaka, H. & Bajjalieh, S.M. (2000) Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J. Biol. Chem., 275, 17195-17200.
60. Ramael, S., Daoust, A., Otoul, C., Toublanc, N., Troenaru, M., Lu, Z.S. & Stockis, A. (2006) Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia, 47, 1128-1135.
61. Reigada, D., Diez-Perez, I., Gorostiza, P., Verdaguer, A., Gomez de Aranda, I., Pineda, O., Vilarrasa, J., Marsal, J., Blasi, J., Aleu, J. & Solsona, C. (2003) Control of neurotransmitter release by an internal gel matrix in synaptic vesicles. Proc. Natl. Acad. Sci. USA, 100, 3485-3490.
62. Riazanski, V., Deriy, L.V., Shevchenko, P.D., Le, B., Gomez, E.A. & Nelson, D.J. (2011) Presynaptic CLC-3 determines quantal size of inhibitory transmission in the hippocampus. Nat. Neurosci., 14, 487-494.
63. Rizo, J. & Rosenmund, C. (2008) Synaptic vesicle fusion. Nat. Struct. Mol. Biol., 15, 665-674.
64. Schenck, S., Wojcik, S.M., Brose, N. & Takamori, S. (2009) A chloride conductance in VGLUT1 underlies maximal glutamate loading into synaptic vesicles. Nat. Neurosci., 12, 156-162.
65. Schivell, A.E., Batchelor, R.H. & Bajjalieh, S.M. (1996) Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J. Biol. Chem., 271, 27770-27775.
66. Schivell, A.E., Mochida, S., Kensel-Hammes, P., Custer, K.L. & Bajjalieh, S.M. (2005) SV2A and SV2C contain a unique synaptotagmin-binding site. Mol. Cell. Neurosci., 29, 56-64.
67. Shi, J., Anderson, D., Lynch, B.A., Castaigne, J.G., Foerch, P. & Lebon, F. (2011) Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Biochem. Soc. T., 39, 1341-1347.
68. Stockis, A., Sargentini-Maier, M.L., Otoul, C., Connor, A., Wilding, I. & Wray, H. (2010) Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. Clin. Ther., 32, 1813-1821.
69. Sudhof, T.C. & Rizo, J. (2011) Synaptic vesicle exocytosis. Cold Spring Harb. Perspect. Biol., 3, a005637.
70. Surges, R., Volynski, K.E. & Walker, M.C. (2008) Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther. Adv. Neurol. Disord., 1, 13-24.
71. Toering, S.T., Boer, K., de Groot, M., Troost, D., Heimans, J.J., Spliet, W.G., van Rijen, P.C., Jansen, F.E., Gorter, J.A., Reijneveld, J.C. & Aronica, E. (2009) Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers. Epilepsia, 50, 1409-1418.
72. Ulloa, C.M., Towfigh, A. & Safdieh, J. (2009) Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr. Dis. Treat., 5, 467-476.
73. UniProt Consortium (2013) UniProt Consortium/SV2A/Q02563.
74. Vautrin, J. (2009) SV2 frustrating exocytosis at the semi-diffusor synapse. Synapse, 63, 319-338.
75. Venkatesan, K., Alix, P., Marquet, A., Doupagne, M., Niespodziany, I., Rogister, B. & Seutin, V. (2012) Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice. J. Neurosci. Res., 90, 2317-2327.
76. van Vliet, E.A., Aronica, E., Redeker, S., Boer, K. & Gorter, J.A. (2009) Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. Epilepsia, 50, 422-433.
77. Wan, Q.F., Zhou, Z.Y., Thakur, P., Vila, A., Sherry, D.M., Janz, R. & Heidelberger, R. (2010) SV2 acts via presynaptic calcium to regulate neurotransmitter release. Neuron, 66, 884-895.
78. Xu, T. & Bajjalieh, S.M. (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat. Cell Biol., 3, 691-698.
79. Yao, J. & Bajjalieh, S.M. (2008) Synaptic vesicle protein 2 binds adenine nucleotides. J. Biol. Chem., 283, 20628-20634.
80. Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R.G. & Bajjalieh, S.M. (2010) Cotrafficking of SV2 and synaptotagmin at the synapse. J. Neurosci., 30, 5569-5578.
81. Zhang, J.Z., Davletov, B.A., Sudhof, T.C. & Anderson, R.G. (1994) Synaptotagmin I is a high affinity receptor for clathrin AP-2: implications for membrane recycling. Cell, 78, 751-760.